Abstract
Respiratory syncytial virus (RSV) is a leading cause of respiratory disease among infants, the elderly and immunocompromised adults. In this study, we assessed the effects of α-galactosylceramide, a known immunoregulatory lipid, on liposomal RSV vaccine-induced responses in BALB/c mice subsequently challenged with RSV. Liposomes containing a recombinant fragment of the RSV G protein were prepared with and without α-galactosylceramide and used to immunize mice by the intranasal route. The inclusion of α-galactosylceramide in the liposomal formulation caused a dramatic reduction in bronchoalveolar lavage neutrophils, but also an increase in eosinophils, following subsequent RSV challenge. The reduction in neutrophils was specific to mice receiving α-galactosylceramide-containing liposomes and was not reproduced in mice administered liposomes containing another α-galactosyl lipid, α-galactosylphosphatidylglyceroylalkylamine. Lung IL-13 mRNA levels were particularly elevated in mice administered α-galactosylceramide-containing liposomes followed by RSV challenge. This study demonstrates a striking ability of α-galactosylceramide to modulate the cellular airway infiltrate in mice immunized with liposomal RSV vaccine followed by RSV challenge.
Original language | English |
---|---|
Pages (from-to) | 7754-7762 |
Number of pages | 9 |
Journal | Vaccine |
Volume | 25 |
Issue number | 45 |
DOIs | |
Publication status | Published - Nov 7 2007 |
Bibliographical note
Funding Information:We are grateful to the Canadian Institutes of Health Research for grant support and to the Kirin Brewery Company, Japan, for generously providing α-GalCer (KRN7000). SM is a recipient of a Thai Royal Golden Jubilee Ph.D. Program Scholarship.
ASJC Scopus Subject Areas
- Molecular Medicine
- General Immunology and Microbiology
- General Veterinary
- Public Health, Environmental and Occupational Health
- Infectious Diseases